ISRG Intuitive Surgical Inc.

U.S. FDA Clears SynchroSeal and E-100 Generator for da Vinci X/Xi Platforms

U.S. FDA Clears SynchroSeal and E-100 Generator for da Vinci X/Xi Platforms

Intuitive’s new sealing instrument and its first generator add versatility1

SUNNYVALE, Calif., Nov. 26, 2019 (GLOBE NEWSWIRE) -- Intuitive (Nasdaq: ISRG), a global technology leader in minimally invasive care and the pioneer of robotic-assisted surgery, today announced U.S. Food and Drug Administration clearance of two innovative technologies for two of the company’s da Vinci® surgical systems to help improve procedures that require sealing.

Intuitive’s E-100 generator is its first internally developed robotic generator to power two key instruments on the da Vinci X® and Xi systems. Vessel Sealer Extend is the flagship instrument in the da Vinci energy sealing portfolio today, and the new SynchroSeal instrument offers enhanced capabilities1 in general surgery.

We are pleased to receive FDA clearance, providing surgeons an additional tool for the X and Xi da Vinci platforms,” said Bob DeSantis, Intuitive’s Senior Vice President and General Manager for Instruments and Accessories.  “We developed SynchroSeal and the E-100 generator to help surgeons quickly seal and transect tissue and vessels, facilitating efficient technique.”

The E-100 is Intuitive’s first generator and is offered as an upgrade to power Vessel Sealer Extend and SynchroSeal. SynchroSeal will enable a surgeon to perform rapid1 one-step sealing and transection with a single pedal press.   

SynchroSeal uses advanced bipolar energy from its raised cut electrode to transect tissue then cool down quickly2, and will allow surgeons to move on to the next step. With its wristed articulation, its rapid sealing cycle, and refined curved jaw, SynchroSeal offers enhanced versatility to the da Vinci Energy portfolio1.

1Compared to Vessel Sealer Extend on Erbe VIO dV

2Data on file

About Intuitive

Intuitive (Nasdaq: ISRG), headquartered in Sunnyvale, Calif., is a global technology leader in minimally invasive care and the pioneer of robotic-assisted surgery. At Intuitive, we believe that minimally invasive care is life-enhancing care. Through ingenuity and intelligent technology, we expand the potential of physicians to heal without constraints.

Intuitive brings more than two decades of leadership in robotic-assisted surgical technology and solutions to its offerings, and develops, manufactures and markets the da Vinci® surgical system and the Ion™ endoluminal system.

About the da Vinci Surgical System

There are several models of the da Vinci surgical system. The da Vinci surgical systems are designed to help surgeons perform minimally invasive surgery. Da Vinci systems offer surgeons high-definition 3D vision, a magnified view, and robotic and computer assistance. They use specialized instrumentation, including a miniaturized surgical camera and wristed instruments (i.e., scissors, scalpels and forceps) that are designed to help with precise dissection and reconstruction deep inside the body.

For more information, please visit the company’s website at .

Forward Looking Statements

This press release contains forward-looking statements, including statements regarding the performance of the company’s products.  These forward-looking statements are based on current expectations and estimates and involve a number of risks and uncertainties that could cause actual results to differ materially from those suggested by the forward-looking statements. These forward-looking statements should, therefore, be considered in light of various important factors, including, but not limited to the risk factors under the heading “Risk Factors” in the company’s annual report on Form 10-K for the year ended December 31, 2018, as updated by the company’s other filings with the Securities and Exchange Commission.  Statements using words such as “estimates,” “projects,” “believes,” “anticipates,” “plans,” “expects,” “intends,” “may,” “will,” “could,” “should,” “would,” “targeted” and similar words and expressions are intended to identify forward-looking statements. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The company undertakes no obligation to publicly update or release any revisions to these forward-looking statements, except as required by law.

Contact

Global Public Affairs

Intuitive Surgical



 

EN
26/11/2019

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Intuitive Surgical Inc.

 PRESS RELEASE

Intuitive Announces Expanded Indications for da Vinci SP

Intuitive Announces Expanded Indications for da Vinci SP FDA clearance expands da Vinci SP indications to include inguinal hernia repair, cholecystectomy, and appendectomy SUNNYVALE, Calif., Dec. 10, 2025 (GLOBE NEWSWIRE) -- Intuitive (NASDAQ: ISRG), a global technology leader in minimally invasive care and the pioneer of robotic-assisted surgery, today announced that the U.S. Food and Drug Administration (FDA) has cleared the da Vinci Single Port (SP) surgical system for use in inguinal hernia repair, cholecystectomy, and appendectomy procedures. These clearances expand da Vinci SP’s ...

Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke

Vital Signs: Actionable charts

n this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.

 PRESS RELEASE

Intuitive Announces Third Quarter Earnings

Intuitive Announces Third Quarter Earnings SUNNYVALE, Calif., Oct. 21, 2025 (GLOBE NEWSWIRE) -- Intuitive (the “Company”) (Nasdaq: ISRG), a global technology leader in minimally invasive care and the pioneer of robotic-assisted surgery, today announced financial results for the quarter ended September 30, 2025. Q3 Highlights Worldwide procedures (da Vinci and Ion combined) grew approximately 20% compared with the third quarter of 2024. Da Vinci procedures grew approximately 19% and Ion procedures grew approximately 52%.The Company placed 427 da Vinci surgical systems, compared with 379 ...

 PRESS RELEASE

Intuitive expands AI and advanced imaging integration in Ion Endolumin...

Intuitive expands AI and advanced imaging integration in Ion Endoluminal System FDA-cleared software release enhances navigation and broadens access to advanced imaging for lung biopsy procedures  SUNNYVALE, Calif., Oct. 08, 2025 (GLOBE NEWSWIRE) -- Intuitive (NASDAQ:ISRG), a global technology leader in minimally invasive care and the pioneer of robotic-assisted surgery, today announced that the U.S. Food & Drug Administration (FDA) has cleared software advancements for the Ion endoluminal system (Ion). Ion, Intuitive’s robotic-assisted bronchoscopy platform, features an ultra-thin, sh...

 PRESS RELEASE

Intuitive Introduces Real-Time Surgical Insights for da Vinci 5

Intuitive Introduces Real-Time Surgical Insights for da Vinci 5 New Force Gauge, In-Console Video Replay, and Network CCM features designed for enhanced efficiency SUNNYVALE, Calif., Sept. 12, 2025 (GLOBE NEWSWIRE) -- Intuitive (Nasdaq: ISRG), a global technology leader in minimally invasive care and the pioneer of robotic-assisted surgery, today announced the first in a series of new software capabilities for da Vinci 5, designed to enhance surgeon and hospital efficiency through the delivery of a range of real-time surgical insights. Da Vinci 5 has more than 10,000 times the computin...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch